In spite of the sarky reply from Sponge, which adds nothing to the discussion, my memory of the G v H studies is basically as follows. There was only a small number of sites involved with Duke Uni being the primary investigator site. The reason for this is because treatment for the disorder is
complex. and only carried out at a small number of locations within the USA. From MESO's point of view this has advantages ; they can run with
the product themselves with only a small sales force being required. It is also correct that, at least some insurance companies had given advanced approval to the treatment. With the 9-1 vote it looked a certainty. Ah well, lives lost but many will be saved in the future. Hope that this answers your queries.
Aplin
Cell Therapy News/Articles, page-15646
-
- There are more pages in this discussion • 2,616 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.49 |
Change
0.140(10.4%) |
Mkt cap ! $1.701B | |||
| Open | High | Low | Value | Volume |
| $1.37 | $1.54 | $1.37 | $23.10M | 15.82M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 24758 | $1.49 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.49 | 73626 | 3 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |